Physician profile
Harmon Patrick
NPI 1174546287
$5,457.67
in general payments reported to CMS, 2019-2025
42 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $1,128 · 2021: $942 · 2022: $770 · 2023: $769 · 2024: $594 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $765.09 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $598.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $404.39 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $400.97 | 2019-2022 | |
| Abbvie INC. | $373.30 | 2021-2023 | |
| Lilly USA, LLC | $359.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $342.21 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $218.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $217.55 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.74 | 2022-2024 | |
| Glaxosmithkline, LLC. | $141.30 | 2019-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $115.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.50 | 2019-2024 | Jardiance |
| Eisai INC. | $96.85 | 2020-2024 | |
| Kowa Pharmaceuticals America, INC. | $94.14 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmon Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.